-
Liraglutide, sold
under the
brand name
Victoza among others, is an anti-diabetic
medication used to
treat type 2 diabetes, and
chronic obesity. It is...
- blood. With the
exception of insulin, most GLP-1
receptor agonists (
liraglutide, exenatide, and others), and pramlintide, all
diabetes medications are...
- It is
currently only
marketed by
Sanofi as Soliqua.
Insulin degludec/
liraglutide is a fixed-dose
combination medication used to
improve glycemic control...
- at Novo
Nordisk led by the
scientist Lotte Bjerre Knudsen developed liraglutide, a glucagon-like peptide-1
receptor agonist that
could be used to treat...
-
Insulin degludec/
liraglutide, sold
under the
brand name Xultophy, is a fixed-dose
combination medication for the
treatment of
adults with type 2 diabetes...
-
diabetes GLP-1
receptor agonists — albiglutide, dulaglutide, exenatide,
liraglutide, lixisenatide,
tirzepatide and semaglutide, the
latter of
which is marketed...
-
Danish scientist and
university professor. She led the
development of
liraglutide and
oversaw the
development of semaglutide, two
notable drugs approved...
- GLP-1
receptor agonists became po****r for
weight loss. The
medications liraglutide, naltrexone/bupropion, orlistat, semaglutide, and
tirzepatide are approved...
- dose
compared to
liraglutide in some of the
measured parameters after ten w****s of
daily intraperitoneal injections with
liraglutide (2.5 or 25 nmol/kg)...
-
Byetta and Bydureon,
manufactured by AstraZeneca),
approved in 2005/2012
liraglutide (Victoza for diabetes,
Saxenda for obesity,
manufactured by Novo Nordisk)...
